Vir Biotechnology (NASDAQ:VIR – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.96) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.13). Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The firm had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $7.53 million. During the same period in the prior year, the business posted ($1.45) EPS. The business’s quarterly revenue was down 19.0% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Vir Biotechnology Stock Performance
VIR stock opened at $7.52 on Thursday. The firm has a 50 day moving average price of $7.89 and a 200-day moving average price of $8.94. Vir Biotechnology has a 52-week low of $7.12 and a 52-week high of $13.09. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1.88 and a beta of 0.46.
Insiders Place Their Bets
Analyst Upgrades and Downgrades
Several research firms recently commented on VIR. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Tuesday, August 20th. Barclays boosted their price objective on shares of Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.80.
Check Out Our Latest Stock Analysis on VIR
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
See Also
- Five stocks we like better than Vir Biotechnology
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to invest in marijuana stocks in 7 stepsĀ
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Are Dividend Achievers? An Introduction
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.